Treatment and Survival Outcomes for Indigenous and Non‐Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross‐Sectional Cohort Study

OBJECTIVES: Our goal was to explore and compare risk factors, patterns of management and survival outcomes in Indigenous compared with non-Indigenous Australian patients using the Victorian Lung Cancer Registry (VLCR). STUDY TYPE: A retrospective observational cohort study of the VLCR. SETTING: Data collected from the VLCR between 18 January 2011 and 24 January 2024. PARTICIPANTS: Primary lung cancer patients in the VLCR. MAIN OUTCOME MEASURES: Patient, disease and management characteristics of Indigenous and non-Indigenous Australian patients. Impacts of patient and clinical variables on treatment and survival, measured by multivariable Cox regression and propensity-matched survival analysis. RESULTS: We included 186 Indigenous and 17,439 non-Indigenous Australian patients. Indigenous Australian lung cancer patients were younger in age {median, 62 years (interquartile range [IQR], 55-69 years) vs. median, 71 years (IQR, 63-77 years); p < 0.001}, had lower socio-economic status (lowest quintile, 57 patients [31%] vs. 3274 patients [19%]; p < 0.001), were more likely to be current smokers (118 patients [65%] vs. 5963 patients [35%]; p < 0.001) and had higher levels of respiratory comorbidity (64 patients [34%] vs. 4088 patients [23%]; p < 0.001). There were no statistically significant differences in receipt of guideline-concordant treatment (82 patients [51%] vs. 8036 patients [56%]; p = 0.12) and survival outcomes (median survival, 1.4 vs. 1.5 years; hazard ratio, 1.06 [95% confidence interval, 0.88-1.27]). CONCLUSION: We found lung cancer patients of Indigenous status were more likely to have demographic disadvantage and clinical risk factors that may contribute to discrepancies in management compared with patients of non-Indigenous status. Identifying barriers to healthcare and treatment in the Indigenous Australian population is an important research priority to improve disparities between the two populations.

Authors

Institutions

Publication Details

Journal
The Medical Journal of Australia
Published
2026-06-28
DOI
https://doi.org/10.5694/mja2.70232
Primary Topic
Global Cancer Incidence and Screening
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment and Survival Outcomes for Indigenous and Non‐Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross‐Sectional Cohort Study

Phillip Parente, Michelle Caldecott, G. Adabi, Rob Blum et al.
The Medical Journal of Australia
Global Cancer Incidence and Screening
article

Treatment and Survival Outcomes for Indigenous and Non‐Indigenous Australians Within the Victorian Lung Cancer Registry: A Retrospective Cross‐Sectional Cohort Study

Phillip Parente, Michelle Caldecott, G. Adabi, Rob Blum, C. Underhill, Sanuki Tissera, Jacqueline Lesage, D Langton, Louis Irving, Melanie Wong, Wasek Faisal, Katharine See, Evangeline Samuel, Matthew Conron, Jessie Zeng, Lisa Briggs, M H Lloyd, J Bartlett, Rob George Stirling, Sagun Parakh, Thomas John, Inger Olesen, Zoe McQuilten, Javier Torres, Jonathan Gillies, Maggie Moore, Tom Wood, S Harden, Gavin Wright, Christopher Lyne, Gary E. Richardson, Justine Clark, Kalinda E. Griffiths, John R. Zalcberg
article en

Abstract

OBJECTIVES: Our goal was to explore and compare risk factors, patterns of management and survival outcomes in Indigenous compared with non-Indigenous Australian patients using the Victorian Lung Cancer Registry (VLCR). STUDY TYPE: A retrospective observational cohort study of the VLCR. SETTING: Data collected from the VLCR between 18 January 2011 and 24 January 2024. PARTICIPANTS: Primary lung cancer patients in the VLCR. MAIN OUTCOME MEASURES: Patient, disease and management characteristics of Indigenous and non-Indigenous Australian patients. Impacts of patient and clinical variables on treatment and survival, measured by multivariable Cox regression and propensity-matched survival analysis. RESULTS: We included 186 Indigenous and 17,439 non-Indigenous Australian patients. Indigenous Australian lung cancer patients were younger in age {median, 62 years (interquartile range [IQR], 55-69 years) vs. median, 71 years (IQR, 63-77 years); p < 0.001}, had lower socio-economic status (lowest quintile, 57 patients [31%] vs. 3274 patients [19%]; p < 0.001), were more likely to be current smokers (118 patients [65%] vs. 5963 patients [35%]; p < 0.001) and had higher levels of respiratory comorbidity (64 patients [34%] vs. 4088 patients [23%]; p < 0.001). There were no statistically significant differences in receipt of guideline-concordant treatment (82 patients [51%] vs. 8036 patients [56%]; p = 0.12) and survival outcomes (median survival, 1.4 vs. 1.5 years; hazard ratio, 1.06 [95% confidence interval, 0.88-1.27]). CONCLUSION: We found lung cancer patients of Indigenous status were more likely to have demographic disadvantage and clinical risk factors that may contribute to discrepancies in management compared with patients of non-Indigenous status. Identifying barriers to healthcare and treatment in the Indigenous Australian population is an important research priority to improve disparities between the two populations.

The Medical Journal of AustraliaVol. 224(7)
Goulburn Valley Health (AU), The Royal Melbourne Hospital (AU), Barwon Health (AU), Flinders University (AU), Northern Health (AU), Epworth Hospital (AU), Peter MacCallum Cancer Centre (AU), Monash Medical Centre (AU), The Alfred Hospital (AU), St Vincent's Hospital Melbourne (AU), Cabrini Hospital (AU), Monash Alfred Psychiatry Research centre (AU), Latrobe Regional Hospital (AU), Eastern Health (AU), Victorian Comprehensive Cancer Centre (AU), Ballarat Health Services (AU), Footscray Hospital (AU), Victorian Aboriginal Health Service (AU), Peninsula Health (AU), Monash Health (AU), Bendigo Health (AU), Olivia Newton-John Cancer Wellness & Research Centre (AU), Alfred Health (AU), Monash University (AU)
Good health and well-being
Openalex Percentile: Top 8%
Global Cancer Incidence and Screening
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.